Hepatitis B Virus (HBV) DNA, Quantitative, Real-Time PCR

The Hepatitis B Virus (HBV) DNA, Quantitative, Real-Time PCR test quantifies HBV DNA to assess the level of viral replication. It is used to confirm and stage chronic HBV infection, characterize carrier states, and detect occult or mutant HBV when serologic findings are incongruent. Quantitative values contribute to prognosis. HBV viral load testing is performed at baseline and during antiviral therapy for on-treatment and post-treatment follow-up to evaluate virologic response and to identify resistance or breakthrough infection. The test is also known as HBV DNA, quantitative or HBV viral load.

Hepatitis B is a DNA virus infection of the liver with worldwide distribution and a clinical range from transient acute illness to chronic infection that increases the risk of cirrhosis and hepatocellular carcinoma. Transmission occurs through blood and other body fluids via percutaneous, sexual, perinatal, and health care exposures. Diagnostic evaluation and disease staging integrate serologic markers (HBsAg, HBeAg, anti-HBc, anti-HBe, anti-HBs) with HBV DNA testing. Real-time PCR provides high analytical sensitivity and specificity and can be performed qualitatively or quantitatively. Quantitative HBV DNA reflects the intensity of viral replication, correlates with HBeAg status and alanine aminotransferase activity, and is associated with risks of disease progression, cirrhosis, and hepatocellular carcinoma. With effective therapy, a decrease of approximately 1–2 log10 within 3–6 months indicates virologic response; failure to decline or a rebound suggests treatment failure or resistance and should prompt reassessment of the regimen. Interpretation of quantitative HBV DNA alongside clinical findings, biochemistry, infection markers, and, when available, liver histology informs prognosis and therapeutic decision-making.